Evidence map›Paper›PMID 32782442›Full record

ArticleClinical and molecular allergy : CMA2020

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma.

David Price, Ludger Klimek, Gabriella Gálffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Ranny van Weissenbruch, Wolfgang Pohl, Hans-Christian Kuhl and 2 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular allergy : CMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05129306 withdrawnnot on this mapstarted 2021, after this paper: background citation

Impact of RYALTRIS® (Olopatadine Hydrochloride / Mometasone Furoate Monohydrate) Nasal Spray on Patients' Reported Outcomes

TypeobservationalSponsorCommunity and Patient Preference Research Pty LtdRan2021 to 2022Enrolled0ConditionsAllergic RhinitisArmsObservational
NCT05146206 completednot on this mapstarted 2021, after this paper: background citation

Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis

TypeobservationalSponsorCommunity and Patient Preference Research Pty LtdRan2021 to 2022Enrolled426ConditionsAllergic RhinitisArmsObservational
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 7 countries.

David PriceCentre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, AB25 2ZD UK.ORCID 0000-0002-9728-9992
Ludger KlimekZentrum für Rhinologie und Allergologie, Wiesbaden, Germany.
Gabriella GálffyPulmonology Hospital, Törökbálint, Hungary.
Melanie EmmeluthMEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.
Arkady KoltunMylan, Inc, Canonsburg, PA USA.
Ferdinand KopietzMEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.
Duc Tung NguyenMEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.
Ranny van WeissenbruchWilhelmina Ziekenhuis Assen, Assen, The Netherlands.
Wolfgang PohlKarl Landsteiner Gesellschaft, Institut für Klinische und experimentelle Pneumologie, Vienna, Austria.
Hans-Christian KuhlMEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.
Glenis ScaddingRoyal National Ear, Nose Throat Hospital, London, England.
Joaquim MullolRhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia Spain.
Mylan (Germany) · DECanisius-Wilhelmina Ziekenhuis · NLHospital Clínic de Barcelona · ESKarl Landsteiner Society · ATMylan (United States) · USRoyal National Throat Nose and Ear Hospital · GBUniversity of Aberdeen · GBZentrum für Rhinologie und Allergologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAsthma affects up to nearly 40% of patients with allergic rhinitis (AR). Poor control of AR symptoms is associated with poor asthma control. The goal of this study was to evaluate the effect of AR treatment with MP-AzeFlu on symptoms of AR as well as symptoms of asthma.

methodsThis prospective study used a visual analog scale (VAS) to assess symptoms of AR and asthma before and after treatment with MP-AzeFlu (Dymista

resultsOf 1103 study participants, 267 (24.2%) had comorbid asthma. These participants reported using a mean of 5.1 puffs of asthma reliever medication in the week before treatment with MP-AzeFlu. A total of 81.8% of patients with comorbid asthma responded to AR therapy (AR-VAS < 50 mm on at least 1 study day). Among patients with AR and comorbid asthma, MP-AzeFlu was associated with improved VAS scores across all study parameters, including AR symptom severity, asthma symptom severity, sleep quality, daily work or school activities, daily social activities, and daily outdoor activities. Asthma symptom severity decreased from a mean of 48.9 mm to 24.1 mm on the VAS. Self-reported frequency of asthma reliever medication use was reduced for 57.6% of participants (n = 139/241).

conclusionMP-AzeFlu used to relieve AR symptoms was associated with reduced asthma symptom VAS scores and frequency of asthma reliever medication usage. Changes in overall symptoms of AR and asthma were correlated.

Indexed as

Allergic rhinitisAsthmaComorbidityDaily activityMP-AzeFluSleep qualityVisual analog scale

Identifiers

PMID32782442
PMCPMC7412849
OpenAlexW3047119187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.